Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inupadenant with Chemotherapy in Nonsquamous NSCLC
NCT05403385Phase 2Active, not recruiting
- Sponsor
- iTeos Therapeutics
- Start
- Aug 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of inupadenant in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by iTeos Therapeutics. Started Aug 2022; status: active, not recruiting.
02
Drugs
inupadenant
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT05403385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05403385.